Quinapril And Hydrochlorothiazide 20/25 Tablet
Product Images NDC 69097-831

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Quinapril And Hydrochlorothiazide 20/25 (NDC 69097-831). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (4d5399c0 8a0b 4140 Bade 1a338866b769 01)

Chemical structure diagram of the active ingredients quinapril and hydrochlorothiazide as depicted for Quinapril and Hydrochlorothiazide 20/12.5 oral tablets by Cipla USA Inc. The diagram shows molecular bonds and components with a molecular weight (M.W.) of 474.98 indicated.*

FDA Label Image

Image (4d5399c0 8a0b 4140 Bade 1a338866b769 02)

Chemical structure diagram of the active ingredient Quinapril and Hydrochlorothiazide, showing the molecular components and arrangement along with the molecular weight of 297.72.*

FDA Label Image

Image (4d5399c0 8a0b 4140 Bade 1a338866b769 03)

A data table comparing the percent of patients experiencing various side effects in controlled trials between Quinapril and Hydrochlorothiazide (N=943) and placebo groups. Side effects listed include headache, dizziness, coughing, fatigue, myalgia, viral infection, rhinitis, nausea and/or vomiting, abdominal pain, black pain, diarrhea, upper respiratory infection, insomnia, somnolence, bronchitis, dyspepsia, asthenia, pharyngitis, vasodilatation, vertigo, and chest pain.*

FDA Label Image

Image (4d5399c0 8a0b 4140 Bade 1a338866b769 04)

A medication side effects text panel listing adverse reactions organized by body systems including cardiovascular, gastrointestinal, nervous/psychiatric, respiratory, integumentary, urogenital system, and other categories. Specific terms such as asthma, malaise, palpitations, tachycardia, and angioedema are included.*

FDA Label Image

Image (4d5399c0 8a0b 4140 Bade 1a338866b769 05)

A text panel listing adverse reactions categorized by body system for Quinapril and Hydrochlorothiazide tablets. It includes symptoms related to cardiovascular, digestive, neurologic, musculoskeletal, hematologic, renal, metabolic, and hypersensitivity effects.*

FDA Label Image

Quinapril And Hydrochlorothiazide 10 mg

Label for Quinapril and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg strength, in a 90-tablet container. The label includes dosage information, storage instructions, and manufacturer details for Cipla USA Inc. The label also features pharmacy dispensing instructions and a barcode.*

FDA Label Image

Quinapril And Hydrochlorothiazide 20 mg

Label for Quinapril and Hydrochlorothiazide 20 mg/12.5 mg oral tablets, USP, produced by Cipla USA Inc. The label indicates a package containing 90 tablets. It includes dosage information, storage instructions at controlled room temperature, manufacturing details for Cipla USA Inc. and InvaGen Pharmaceuticals Inc., and features a barcode and QR code.*

FDA Label Image

Quinapril And Hydrochlorothiazide 25

Packaging label for Quinapril and Hydrochlorothiazide Tablets, USP, with a strength of 20 mg/25 mg. The label indicates a quantity of 90 tablets and is manufactured for Cipla USA Inc. It includes storage instructions, dosage reference, barcode, and manufacturer information. The label also shows the NDC number 69097-831-05 and a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.